Edition:
United Kingdom

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
4:08pm GMT
Change (% chg)

$0.15 (+8.11%)
Prev Close
$1.85
Open
$1.97
Day's High
$2.17
Day's Low
$1.95
Volume
413,606
Avg. Vol
342,890
52-wk High
$2.95
52-wk Low
$0.88

Chart for

About

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid... (more)

Overall

Beta: 2.92
Market Cap(Mil.): $22.01
Shares Outstanding(Mil.): 21.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.75 16.58
EPS (TTM): -- -- --
ROI: -- 3.21 10.60
ROE: -- 4.54 14.19

BRIEF-OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

* ONCOSEC PROVIDES ENCOURAGING CLINICAL OBSERVATIONS RELATED TO TRIPLE NEGATIVE BREAST CANCER STUDY Source text for Eikon: Further company coverage:

2:35pm GMT

BRIEF-Oncosec Plans To Conduct A Second Clinical Trial In Triple Negative Breast Cancer In 2018​

* ONCOSEC MEDICAL INC - PLAN TO CONDUCT A SECOND CLINICAL TRIAL IN TRIPLE NEGATIVE BREAST CANCER IN 2018​

03 Jan 2018

BRIEF-OncoSec Medical files for offering of up to 6.83 mln shares

* OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing Source: (http://bit.ly/2hEfpJ6) Further company coverage:

16 Nov 2017

BRIEF-Oncosec announces positive follow-up data from phase 2 trial of Immunopulse il-12

* Oncosec announces positive updated long-term follow-up data from phase 2 trial of Immunopulse il-12 in combination with pembrolizumab demonstrating a progression free survival rate (PFS) of 57% at 15 months in predicted anti-pd-1 non-responder melanoma p Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Oncosec appoints Daniel O'Connor as CEO

* Oncosec appoints Daniel J. O'Connor as chief executive officer to lead next stage of growth as a fully integrated late stage development and commercial company

07 Nov 2017

BRIEF-Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical

* Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical Inc, as of October 22, 2017‍​ Source text: [http://bit.ly/2zVkxvZ] Further company coverage:

31 Oct 2017

BRIEF-OncoSec Q4 loss per share $0.28

* OncoSec announces fourth quarter and year end financial results for fiscal year 2017

25 Oct 2017

BRIEF-ONCOSEC ANNOUNCES $7.1 MLN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

* ONCOSEC ANNOUNCES $7.1 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

23 Oct 2017

BRIEF-Oncosec presents positive Phase 2 data for immunopulse® IL-12 in combination with Pembrolizumab

* Oncosec presents positive Phase 2 data for Immunopulse® IL-12 in combination with Pembrolizumab demonstrating a best overall response rate (BORR) of 50 pct in predicted anti-PD-1 non-responder melanoma patients

19 Oct 2017

BRIEF-OncoSec appoints industry veteran Annalisa Jenkins MBBS, FRCP to board of directors

* OncoSec appoints industry veteran Annalisa Jenkins MBBS, FRCP to board of directors Source text for Eikon: Further company coverage:

05 Sep 2017

Earnings vs. Estimates